Pekin Hardy Strauss’s Prime Medicine PRME Stock Holding History

Pekin Hardy Strauss’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$350K	Buy	+114,500	New	+$380K	0.03%	354

Other funds holding PRME

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Alessandra Capital Management Torrance, California $142M AUM 42.73% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

MAM

Milestone Asset Management Pittsburgh, Pennsylvania $631M AUM 19.95% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Pekin Hardy Strauss's PRME Position: Q3 2026 in Review

Pekin Hardy Strauss opened a new position in Prime Medicine (PRME) in Q3 2026: 114,500 shares worth $350K. The stake represents 0.03% of the portfolio and ranks #354 among its holdings.

46 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

Pekin Hardy Strauss held 114,500 shares of Prime Medicine worth $350K as of Q3 2026.
Prime Medicine was a new Pekin Hardy Strauss position in Q3 2026.
Prime Medicine made up 0.03% of Pekin Hardy Strauss's portfolio in Q3 2026, its #354 holding.
46 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Pekin Hardy Strauss's 13F filing for Q3 2026, filed 2 Nov 2026.